Literature DB >> 29956206

NAFLD Related-HCC: The Relationship with Metabolic Disorders.

Xiang Zhang1.   

Abstract

Obesity increases death rates of all cancers including non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (NAFLD-HCC). NAFLD is considered as hepatic manifestation of metabolic syndrome and is a multi-system disease. Recent prevalence studies have intensively reported the association of obesity, metabolic risk factors and HCC incidence and mortality. Mechanistic studies suggested that immune response, PI3K/AKT/mTOR/PTEN pathway, mitochondrial dysfunction and genetic alterations are important mediators in the progression of NAFLD-HCC from metabolic disorder. In this book chapter, we attempt to collate current research on NAFLD-HCC that lead to our understandings on how metabolic disorders may intersect with cancer development. We also discussed the prevention options of NAFLD-HCC in view of obesity and metabolic disorder. These studies have extended our knowledge on the complicated mechanism of NAFLD and HCC, and provided the prevention options of NAFLD-HCC in patients with obesity and metabolic diseases.

Entities:  

Keywords:  Immune response; Metabolic syndrome; NAFLD-related HCC; Obesity

Mesh:

Substances:

Year:  2018        PMID: 29956206     DOI: 10.1007/978-981-10-8684-7_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

1.  The major cap-binding protein eIF4E regulates lipid homeostasis and diet-induced obesity.

Authors:  Crystal S Conn; Haojun Yang; Harrison J Tom; Kenji Ikeda; Juan A Oses-Prieto; Hieu Vu; Yasuo Oguri; Supna Nair; Ryan M Gill; Shingo Kajimura; Ralph J DeBerardinis; Alma L Burlingame; Davide Ruggero
Journal:  Nat Metab       Date:  2021-02-18

2.  Unusual Presentation of Hepatocellular Carcinoma and Rare Metastasis to the Masticatory Space.

Authors:  Urban Čizmarević; Nina Hanžič; Beno Polanec; Mitja Rupreht
Journal:  Cureus       Date:  2019-09-30

Review 3.  Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.

Authors:  Scott M Williams; Aikaterini Eleftheriadou; Uazman Alam; Daniel J Cuthbertson; John P H Wilding
Journal:  Diabetes Ther       Date:  2019-09-24       Impact factor: 2.945

4.  The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.

Authors:  Xiaotian Shen; Beiyuan Hu; Jing Xu; Wei Qin; Yan Fu; Shun Wang; Qiongzhu Dong; Lunxiu Qin
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

Review 5.  Translational Control in Liver Disease.

Authors:  Alexandra Balvey; Mercedes Fernandez
Journal:  Front Physiol       Date:  2021-11-29       Impact factor: 4.566

6.  Clinical Significance and Potential Mechanisms of ATP Binding Cassette Subfamily C Genes in Hepatocellular Carcinoma.

Authors:  Xin Zhou; Jia-Mi Huang; Tian-Man Li; Jun-Qi Liu; Zhong-Liu Wei; Chen-Lu Lan; Guang-Zhi Zhu; Xi-Wen Liao; Xin-Ping Ye; Tao Peng
Journal:  Front Genet       Date:  2022-03-07       Impact factor: 4.599

Review 7.  Obesity Management in the Primary Prevention of Hepatocellular Carcinoma.

Authors:  Elizabeth R M Zunica; Elizabeth C Heintz; Christopher L Axelrod; John P Kirwan
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

8.  The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Shelley E Harris; Toryn M Poolman; Anastasia Arvaniti; Roger D Cox; Laura L Gathercole; Jeremy W Tomlinson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-08-05       Impact factor: 4.052

Review 9.  Mitochondrial Dysfunction in the Transition from NASH to HCC.

Authors:  Mélissa Léveillé; Jennifer L Estall
Journal:  Metabolites       Date:  2019-10-16

10.  Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus: A protocol for systematic review and network meta-analysis.

Authors:  Su-Tong Liu; Kai-Qi Su; Li-Hui Zhang; Ming-Hao Liu; Wen-Xia Zhao
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.